Search in:

Advanced search

Patient Preference and Adherence Volume 13, 2019 - Issue

Submit an article Journal homepage

Open access

135

Views

CrossRef citations to date

Altmetric

Original Research

Health-related quality-of-life and treatment satisfaction of individuals with hemophilia A treated with turoctocog alfa pegol (N8-GP): a new recombinant extended half-life FVIII

Susan Kearney1 Center for Bleeding and Clotting Disorders, Children’s Hospital Minnesota, Minneapolis, MN, USA

Leslie J Raffini2 Division of Hematology, The Children’s Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA

Tan P Pham3 Mapi (an Icon plc company), Boston, MA, USA

Xin Ying Lee4 Global Biopharm Patient Access, Biopharm Operations, Novo Nordisk A/S, Copenhagen, Denmark

Sylvia von Mackensen5 Department of Medical Psychology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany, [email protected]Correspondence[email protected]

Andrea Landorph6 Medical & Science, Biopharm Operations, Novo Nordisk A/S, Copenhagen, Denmark

Hideyuki Takedani7 Department of Joint Surgery, Research Hospital of the Institute of Medical Science, The University of Tokyo, Tokyo, Japan

Johannes Oldenburg8 Institute of Experimental Haematology and Transfusion Medicine, University Clinic Bonn, Bonn, Germany

show all

Pages 497-513 | Published online: 09 Apr 2019

Cite this article
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF View EPUB EPUB

References

SrivastavaABrewerAKMauser-BunschotenEPGuidelines for the management of hemophiliaHaemophilia2013191e1e4710.1111/j.1365-2516.2012.02909.x22776238
PubMed Web of Science ®Google Scholar
van GenderenFRFischerKHeijnenLPain and functional limitations in patients with severe haemophiliaHaemophilia200612214715310.1111/j.1365-2516.2006.01203.x16476089
PubMed Web of Science ®Google Scholar
WitkopMGuelcherCForsythATreatment outcomes, quality of life, and impact of hemophilia on young adults (aged 18–30 years) with hemophiliaAm J Hematol201590Suppl 2S3S1010.1002/ajh.2422026619194
PubMed Web of Science ®Google Scholar
HolsteinKvon MackensenSBokemeyerCLangerFThe impact of bleeding disorders on the socioeconomic status of adult patients. Results of a comparative single centre cohort studyHamostaseologie2017999910.5482/HAMO-16-12-0047
Web of Science ®Google Scholar
MannucciPMFranchiniMPresent and future challanges in the treatment of haemophilia: a clinician’s perspectiveBlood Transfusion201311Suppl 4s77s8110.2450/2013.012s24333317
PubMed Web of Science ®Google Scholar
MahlanguJYoungGHermansCBlanchetteVBerntorpESantagostinoEDefining extended half-life rFVIII – a critical review of the evidenceHaemophilia201824334835810.1111/hae.1343829633467
PubMed Web of Science ®Google Scholar
du TreilSRiceJLeissingerCAQuantifying adherence to treatment and its relationship to quality of life in a well-characterized haemophilia populationHaemophilia200713549350110.1111/j.1365-2516.2007.01526.x17880435
PubMed Web of Science ®Google Scholar
DuncanNShapiroAYeXEpsteinJLuoMPTreatment patterns, health-related quality of life and adherence to prophylaxis among haemophilia A patients in the United StatesHaemophilia201218576076510.1111/j.1365-2516.2012.02813.x22548353
PubMed Web of Science ®Google Scholar
GringeriALundinBvon MackensenSMantovaniLMannucciPMA randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study)J Thromb Haemost20119470071010.1111/j.1538-7836.2011.04214.x21255253
PubMed Web of Science ®Google Scholar
Manco-JohnsonMJAbshireTCShapiroADProphylaxis versus episodic treatment to prevent joint disease in boys with severe hemophiliaN Engl J Med2007357653554410.1056/NEJMoa06765917687129
PubMed Web of Science ®Google Scholar
TiedeABrandBFischerREnhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia AJ Thromb Haemost201311467067810.1111/jth.1216123398640
PubMed Web of Science ®Google Scholar
MeunierSAlameluJEhrenforthSSafety and efficacy of a glycoPEGylated rFVIII (turoctocog alpha pegol, N8-GP) in paediatric patients with severe haemophilia AThromb Haemost201711791705171310.1160/TH17-03-016628692108
PubMed Web of Science ®Google Scholar
GiangrandePAndreevaTChowdaryPClinical evaluation of glycoPEGylated recombinant FVIII: efficacy and safety in severe haemophilia AThromb Haemost2017117225226110.1160/TH16-06-044427904904
PubMed Web of Science ®Google Scholar
von MackensenSBullingerMHaemo-QoL GroupDevelopment and testing of an instrument to assess the quality of life of children with haemophilia in Europe (Haemo-QoL)Haemophilia200410Suppl 1172510.1111/j.1355-0691.2004.00875.x
PubMed Web of Science ®Google Scholar
von MackensenSGringeriAQuality of life in hemophiliaPreedyVWatsonRHandbook of Disease Burdens and Quality of Life MeasuresNew York, NYSpringer201018951920
Google Scholar
von MackensenSGringeriAMantovaniLDevelopment and validation of the first treatment satisfaction scale for adult haemophiliacs (Hemo-SatA)Haemophilia200410Suppl 312615479385
PubMed Web of Science ®Google Scholar
von MackensenSGringeriASkovlundSAssessment of treatment satisfaction in patients with haemophilia – development and validation of the first disease-specific questionnaire (Hemo-SatA)J Thromb Haemost20053Suppl115634257
PubMed Web of Science ®Google Scholar
SantagostinoELentzSRBuskAKRegnaultAIorioAAssessment of the impact of treatment on quality of life of patients with haemophilia A at different ages: insights from two clinical trials on turoctocog alfaHaemophilia201420452753410.1111/hae.1237124471912
PubMed Web of Science ®Google Scholar
WyrwichKWKrishnanSAugustePChanges in health-related quality of life with treatment of longer-acting clotting factors: results in the A-LONG and B-LONG clinical studiesHaemophilia201622686687210.1111/hae.1298727385432
PubMed Web of Science ®Google Scholar
RofailDRegnaultABaladiJ-FBerdeauxGAssessing treatment satisfaction during a product’s lifecycle to facilitate market access: definitions, frameworks, and measurementISPOR Connect2010163710
Google Scholar
ShikiarRRentzAMSatisfaction with medication: an overview of conceptual, methodologic, and regulatory issuesValue Health20047220421510.1111/j.1524-4733.2004.72252.x15164810
PubMed Web of Science ®Google Scholar
MinersAHSabinCATolleyKHJenkinsonCKindPLeeCAAssessing health-related quality-of-life in individuals with haemophiliaHaemophilia19995637838510583523
PubMed Web of Science ®Google Scholar
GringeriAvon MackensenSAuerswaldGHealth status and health-related quality of life of children with haemophilia from six West European countriesHaemophilia200410Suppl 1263314987246
PubMed Web of Science ®Google Scholar

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Health-related quality-of-life and treatment satisfaction of individuals with hemophilia A treated with turoctocog alfa pegol (N8-GP): a new recombinant extended half-life FVIII

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Health-related quality-of-life and treatment satisfaction of individuals with hemophilia A treated with turoctocog alfa pegol (N8-GP): a new recombinant extended half-life FVIII

References

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date